ISIN:DE000A3CMGM5

EQS-News: APONTIS PHARMA schließt fünfjährige Distributions- und Vermarktungsvereinbarung für zwei Asthma-Arzneimittel mit Novartis und erhöht Prognose

Retrieved on: 
Wednesday, April 10, 2024
Monheim, Rhein, Pharmazie, Ticker, Novartis, Gesellschaft mit beschränkter Haftung, Vertrag, Distribution, Vermarktung, Arzneimittel, Indikation, Asthma bronchiale, Gesellschaft, Prognose, Chief, Executive, Officer, Produkt, Beitrag, Versorgung, Menschen, Kooperation, Pharmahersteller, Single, Jacques Pills, Wirkstoff, Patient, Komplikation, Sterblichkeit, Therapie, Portfolio, Fokus, Hypertonie, Information

EQS-News: APONTIS PHARMA expects profitable growth again in 2024

Retrieved on: 
Wednesday, April 10, 2024
EUR, Annual report, Tax, Marketing, Ticker, Growth, Physician, Depreciation, Pharmaceutical industry

APONTIS PHARMA closed the 2023 financial year with a consolidated net loss of EUR 11.3 million (2022: consolidated net income of EUR 2.7 million).

Key Points: 
  • APONTIS PHARMA closed the 2023 financial year with a consolidated net loss of EUR 11.3 million (2022: consolidated net income of EUR 2.7 million).
  • Bruno Wohlschlegel, Chief Executive Officer of APONTIS PHARMA AG: “The 2023 financial year was characterized by significant changes for APONTIS PHARMA.
  • Following the successful implementation of the performance and efficiency improvement program earlier than planned, APONTIS PHARMA has laid the foundations for future profitable growth in Single Pill combinations.
  • As such, we launched our 15th Single Pill combination on the German market in March and continue to see considerable growth potential for Single Pill combinations from APONTIS PHARMA.

EQS-News: APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast

Retrieved on: 
Wednesday, April 10, 2024
Asthma, Marketing, Ticker, Pharmaceutical industry

APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5 ) has entered into a five-year agreement with Novartis Pharma GmbH to take over the distribution and marketing of the patent-protected medications Enerzair® and Atectura® in the asthma indication for Germany.

Key Points: 
  • APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5 ) has entered into a five-year agreement with Novartis Pharma GmbH to take over the distribution and marketing of the patent-protected medications Enerzair® and Atectura® in the asthma indication for Germany.
  • Bruno Wohlschlegel, Chief Executive Officer of APONTIS PHARMA AG: “Taking over the distribution and marketing of the products Enerzair® and Atectura® from Novartis for a five-year period is an important contribution to the patient-oriented care of people with asthma in Germany.
  • Novartis and APONTIS PHARMA have a long-standing cooperation in the marketing of products, which will now be continued.
  • I am pleased that our new multi-channel-based go-to-market model in particular has convinced Novartis to transfer distribution and marketing to APONTIS PHARMA.”

EQS-News: APONTIS PHARMA successfully completes performance and efficiency improvement program

Retrieved on: 
Tuesday, February 6, 2024
Growth, Physician, Ticker, Marketing, CPO, EUR, Management

Monheim am Rhein, 6 February 2024 – APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5 ) has successfully completed the performance and efficiency improvement program announced in summer 2023.

Key Points: 
  • Monheim am Rhein, 6 February 2024 – APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5 ) has successfully completed the performance and efficiency improvement program announced in summer 2023.
  • Bruno Wohlschlegel, Chief Executive Officer of APONTIS PHARMA AG: “At the end of the past year, we presented a comprehensive program to improve performance and efficiency, based on a thorough analysis of the weaknesses identified in the situation at the time.
  • The implementation of the performance and efficiency improvement program at EUR 5.6 million is at the lower end of the expenses planned for the 2023 financial year.
  • Bruno Wohlschlegel continued: “Following the implementation of the comprehensive performance and efficiency improvement program, APONTIS PHARMA is a new company.

EQS-News: APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month figures for 2023 and new sales and earnings forecast for 2023 published

Retrieved on: 
Saturday, December 30, 2023
Marketing, Partnership, Physician, Advertising, Growth, Medicine, Ticker, Communication

An analysis of sales and advertising activities has shown that the current marketing and sales concept has significant potential for optimization.

Key Points: 
  • An analysis of sales and advertising activities has shown that the current marketing and sales concept has significant potential for optimization.
  • In the future, the development of the portfolio will be driven by targeted campaigns for specific, high-growth Single Pills.
  • The market changes resulting from the pandemic also led to a permanent loss of 20% of sales force contacts at APONTIS PHARMA.
  • APONTIS PHARMA recorded a 37.1% decline in total sales to EUR 27.1 million in the first nine months of 2023 (9M 2022: EUR 43.1 million).

EQS-News: APONTIS PHARMA stellt Details des Restrukturierungs- und Effizienzprogramms vor – Neun-Monatszahlen 2023 sowie neue Umsatz- und Ergebnisprognose für 2023 veröffentlicht

Retrieved on: 
Wednesday, December 13, 2023
Gesellschaft, HCT, M, Single, Verlust, Vorstand, Umsetzung, Prognose, Prozentzeichen, Reduktion, Pill, Fachgesellschaft, Wachstum, Beendigung, Therapie, Marketing, Vertrieb, Implementierung, Positionierung, Voraussetzung, Pharmazie, EBITDA, Partnerschaft, Leitlinie, Zusammenarbeit, Zahl, Evidenz, Summe, Medizin, Umsatz, Nachfrage, Lipide, Million, Kontakt, Gesamtumsatz, Monat, Ansatz, Biophysik, Krankenkasse

EQS-News: APONTIS PHARMA confirms preliminary figures – H1 2023 sales and earnings decline

Retrieved on: 
Thursday, August 10, 2023
Total, Tax, Monheim am Rhein, Co-marketing, AstraZeneca, EUR, EBITDA, Budesonide/glycopyrronium bromide/formoterol, Publishing, APPH, Depreciation, Growth, Lithium, Film industry

APONTIS PHARMA AG (ticker APPH / ISIN DE000A3CMGM5 ), a leading pharmaceutical company specializing in Single Pills in the German market, has confirmed the preliminary figures it announced in July by publishing its half-year report.

Key Points: 
  • APONTIS PHARMA AG (ticker APPH / ISIN DE000A3CMGM5 ), a leading pharmaceutical company specializing in Single Pills in the German market, has confirmed the preliminary figures it announced in July by publishing its half-year report.
  • The company reported a total decline in sales of 32% to EUR 19.1 million in the first half of 2023 (6M 2022: EUR 28.1 million).
  • In the cooperation business, APONTIS PHARMA generated sales revenues of EUR 5.9 million (6M 2022: EUR 9.1 million).
  • By contrast, earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR -4.0 million were mainly influenced by the development of sales (6M 2022: EUR 3.2 million).